ICH E6 (R3) Guideline on good clinical practice (GCP)
International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use
GOOD CLINICAL PRACTICE (GCP) E6(R3) Step 5
23 January 2025. Date for coming into effect 23 July 2025
ICH E6(R3) introduces innovative provisions designed to apply across various types and settings of clinical trials, ensuring continued relevance in the face of ongoing technological and methodological advancements. This guideline provides a new language to facilitate innovations in clinical trial design, technology, and operational approaches. It encourages a risk-based and proportionate approach to conducting clinical trials, promoting fit-for-purpose solutions. It fosters transparency through clinical trial registration and result reporting and offers additional guidance to enhance the informed consent process.
The overarching principles and Annex 1, adopted by ICH and CHMP, came into effect on 23 July 2025.
With the public consultation now concluded, the Annex 2 is expected to be finalised later in 2025.
I. INTRODUCTION
II. PRINCIPLES OF ICH GCP
III. ANNEX 1
1. INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE (IRB/IEC)
2. INVESTIGATOR
3. SPONSOR
4. DATA GOVERNANCE – INVESTIGATOR AND SPONSOR
Appendix A. INVESTIGATOR’S BROCHURE
Appendix B. CLINICAL TRIAL PROTOCOL AND PROTOCOL AMENDMENT(S)
Appendix C. ESSENTIAL RECORDS FOR THE CONDUCT OF A CLINICAL TRIAL
GLOSSARY
© European Medicines Agency, 2025. Reproduction is authorised provided the source is acknowledged.
Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000
Clinical Research News
Upcoming Clinical Trials
-
Wake Forest University Health SciencesNot yet recruiting
-
Wake Forest University Health SciencesNot yet recruiting
-
West China Second University HospitalNot yet recruitingSleep | Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma | Pathological Response
-
M.D. Anderson Cancer CenterRecruitingStem Cell Transplantation | Gemcitabine | Docetaxel | Carboplatin | Pediatric Relapsed | Prospective Observational Study | Melphalan | Refractory GermUnited States
-
Washington University School of MedicineCompass TherapeuticsNot yet recruitingMetastatic Colorectal Cancer | Colorectal CancerUnited States
-
AstraZenecaNot yet recruitingType 2 Diabetes MellitusUnited States, Spain, Denmark, Hungary, China, Taiwan, South Africa, Greece, Argentina, Japan, South Korea, Turkey (Türkiye)
-
Arcus Biosciences, Inc.Not yet recruiting
-
West China Second University HospitalNot yet recruitingGastric Adenocarcinoma | Emotional Distress | Gastroesophageal Junction Adenocarcinoma | Pathologic Response
-
West Virginia UniversityNot yet recruitingIrritable Bowel Syndrome (IBS-C)United States
-
Arrowhead PharmaceuticalsNot yet recruitingHealthy Participants
-
AstraZenecaNot yet recruitingType 2 Diabetes MellitusUnited States, Denmark, United Kingdom, Hungary, Brazil, Vietnam, Malaysia, Taiwan, China, Germany, Greece, Poland, Ukraine, Czechia, Japan, Puerto Rico, Argentina, South Korea
-
Boehringer IngelheimNot yet recruitingObesity | OverweightUnited States, Australia, United Kingdom, Canada, China, New Zealand, South Korea
Clinical Research Jobs
-
France - Evreux
-
United StatesCanada - Québec - Quebec
-
Romania - New York - Cluj-Napoca
-
Japan - Tokyo
-
India - Bengaluru
-
United States - North Carolina - Morrisville
-
China